Each infusion of the product needs 5 or six grams of protein and the protein is very difficult to separate from the endotoxins used in the e coli process. I am sure when Pfizer bought Esperion they didn't realize the difficulties that they encountered.
Usually when a company undergoes a study they say how many people will I have to treat for what period of time, to show efficacy. Esperion said how many vials of Milano do I have, and what is the minimum number of people can I treat in the shortest amount of time to perhaps a get a signal, with the number of vials we have in our refrigerator because we can't make any more.
That is why there was such amazement that the study worked.
This isn't an orphan disease that they will be able to charge 400 thousand a person, like Alexion. The cost to produce the protein will have to make economic sense.
Market Data 
Markets 
AI
